GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CytoDyn (CYDY) shares

Learn how to easily invest in CytoDyn shares.

CytoDyn Inc is a biotechnology business based in the US. CytoDyn shares (CYDY) are listed on the OTCQB and all prices are listed in US Dollars. CytoDyn employs 24 staff and has a trailing 12-month revenue of around USD$41,000.

How to buy shares in CytoDyn

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYDY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted CytoDyn's stock price?

Since the stock market crash in March caused by coronavirus, CytoDyn's stock price has had significant positive movement.

Its last market close was $1.39, which is 21.22% up on its pre-crash value of $1.095 and 75.95% up on the lowest point reached during the March crash when the stocks fell as low as $0.79.

If you had bought $1,000 worth of CytoDyn stocks at the start of February 2020, those stocks would have been worth $642.58 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $917.50.

Is it a good time to buy CytoDyn stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CytoDyn shares at a glance

Information last updated 2021-10-16.
Latest market close$1.39
52-week range$1.25 - $7.40
50-day moving average $1.73
200-day moving average $2.02
Wall St. target price$4.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.26

CytoDyn stock price (OTCQB: CYDY)

Use our graph to track the performance of CYDY stocks over time.

CytoDyn price performance over time

Historical closes compared with the close of $1.39 from 2021-10-18

1 week (2021-10-12) -16.27%
1 month (2021-09-17) -30.85%
3 months (2021-07-19) -16.27%
6 months (2021-04-19) -60.29%
1 year (2020-10-19) -50.71%
2 years (2019-10-18) 348.39%
3 years (2018-10-19) 162.26%
5 years (2016-10-19) 110.61%

CytoDyn financials

Revenue TTM $41,000
Gross profit TTM $0
Return on assets TTM -57.11%
Return on equity TTM 0%
Profit margin 0%
Book value $0.01
Market capitalisation $937.5 million

TTM: trailing 12 months

CytoDyn share dividends

We're not expecting CytoDyn to pay a dividend over the next 12 months.

CytoDyn share price volatility

Over the last 12 months, CytoDyn's shares have ranged in value from as little as $1.25 up to $7.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.8159. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.

CytoDyn overview

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site